Skip to main content

Table 2 General distribution and outcome type of new cases of drug-resistant tuberculosis, according to characteristics of block II, Brazil, 2013 and 2014

From: Brazilian cohort study of risk factors associated with unsuccessful outcomes of drug resistant tuberculosis

  Total (980 cases) Success treatment Lost to follow-up Failure Death
  N % N % N % N % N %
Block II           
Cavitation           
Yes 753 76.8 474 62.9 127 16.9 62 8.2 90 12.0
No 227 23.2 147 64.8 36 15.9 14 6.2 30 13.2
Bilateral disease           
Yes 614 62.7 369 60.1 101 16.4 57 9.3 87 14.2
No 366 37.3 252 68.9 62 16.9 19 5.2 33 9.0
Resistance type           
Primary 231 23.6 166 71.9 32 13.9 15 6.5 18 7.8
Acquired 749 76.4 455 60.7 131 17.5 61 8.1 102 13.6
Initial resistance pattern           
MDR/RR 965 98.5 616 63.8 162 16.8 74 7.7 113 11.7
XDR 15 1.5 5 33.3 1 6.7 2 13.3 7 46.7
Initial scheme type           
Individualized 873 89.1 558 63.9 142 16.3 66 7.6 107 12.3
Standardized 107 10.9 63 58.9 21 19.6 10 9.3 13 12.1
Fluoroquinolone treatment           
Only used Lfx or Mfx 935 95.4 594 63.5 158 16.9 70 7.5 113 12.1
Only used Ofx 12 1.2 6 50.0 3 25.0 2 16.7 1 8.3
Used more than one fluorquinolone or did not use 33 3.4 21 63.6 2 6.1 4 12.1 6 18.2
Injectable drug treatment           
Just used Am 242 24.7 151 62.4 41 16.9 17 7.0 33 13.6
Only used S 607 61.9 391 64.4 103 17.0 41 6.8 72 11.9
Only used Cm 49 5.0 30 61.2 10 20.4 5 10.2 4 8.2
Used more than one injectable or did not use 82 8.4 49 59.8 9 11.0 13 15.9 11 13.4
Total 980 100.0 621 63.4 163 16.6 76 7.8 120 12.2
  1. MDR multidrug resistant, RR resistant to rifampicin diagnosed by GeneXpert MTB/RIF® (RR), XDR extensively resistant, Lfx levofloxacin, Mfx moxifloxacin, Ofx ofloxacino, Am amikacin, S streptomycin, Cm capreomycin